J&J/Cordis Trufill Embolic Agent PMA Gains Panel Okay For Brain AVMs
This article was originally published in The Gray Sheet
Executive Summary
Approval of Cordis' Trufill liquid embolic agent should be conditioned on the company's completion of studies requested by FDA in an earlier deficiency letter on the firm's premarket approval application, the agency's Neurological Devices Advisory Panel agreed at its May 11 meeting in Gaithersburg, Maryland.
You may also be interested in...
Cordis Trufill Embolic System Approval Is Fledgling Neurovascular Unit's First
Cordis Neurovascular plans to launch the Trufill n-butyl cyanoacrylate (n-BCA) liquid embolic system for treatment of cerebral arteriovenous malformations (AVMs) the week of Oct. 2 following FDA approval of the neurovascular glue Sept. 26.
Cordis Trufill Embolic System Approval Is Fledgling Neurovascular Unit's First
Cordis Neurovascular plans to launch the Trufill n-butyl cyanoacrylate (n-BCA) liquid embolic system for treatment of cerebral arteriovenous malformations (AVMs) the week of Oct. 2 following FDA approval of the neurovascular glue Sept. 26.
Micro Therapeutics Inc. To Initiate Embolyx U.S.Trials In Support of PMA
Micro Therapeutics Inc. is preparing to begin a multi-center pivotal trial this year of the Embolyx liquid embolic system for hypervascular meningioma.